Bloomberg Intelligence: Ackman Pitches UMG Deal (Podcast)

$65 billion: Pershing Square (Bill Ackman) has pitched a deal to combine Universal Music Group with a U.S.-listed acquisition vehicle to move UMG's listing to the U.S. $5 billion: Gilead agreed to acquire private German biotech Tubulis for up to $5B to strengthen its oncology pipeline. Novo Nordisk will price a new high‑dose Wegovy at $399/month cash, undercutting most doses of Eli Lilly’s Zepbound. Anthropic plans to work with Broadcom and Google to power operations, and data‑center capex among the 14 largest public operators is projected near $750B this year versus ~$450B last year, signaling continued digital infrastructure investment.

Analysis

A major US listing or consolidation vehicle for a large music-catalog owner would functionally reset valuation comps for content-heavy media assets and create a liquid financing pathway for further rights aggregation. That flow of capital will encourage private catalog owners to sell into public markets, compressing acquisition yields and increasing bargaining power versus small streaming platforms; within 6–18 months expect renewed M&A chatter and a re-steepening of media M&A multiples relative to historical European peers.

The Anthropic–cloud–silicon axis materially raises demand for differentiated inference hardware and bespoke network stacks, an outcome that favors integrated semiconductor/firmware vendors with broad OEM relationships. Over the next 12–24 months this should push ASPs and lead times for high-performance interconnect and accelerator components higher, benefiting suppliers with constrained capacity and integrated software hooks while pressuring generic server OEM margins.

In healthcare, tactical pricing moves in the obesity market accelerate payer negotiations and will compress gross-to-net for incumbents if competitors match prices or payers demand outcome-based contracts. Smaller biotech M&A continues to be catalytic but binary; near-term upside for acquirers hinges on disciplined staged milestones and realistic integration timelines, while the largest tail risk remains regulatory/backlash on pricing and reimbursement that can flip economics inside 6–12 months.

Key Decisions for Investors

• Long AVGO (6–18 months): buy AVGO or buy 12–18 month calls (5–10% OTM). Thesis: capture elevated ASPs and durable revenue from AI/data-center silicon; R/R ~ +20% upside vs -12% downside if Anthropic/partner plans shift or supply normalizes. Size 1.5–3% notional, hedge with 3–6 month put spread to cap drawdown.
• Long GILD (12–24 months): buy stock on pullbacks or buy 9–18 month calls. Thesis: disciplined bolt-on M&A for ADC-like assets is accretive if milestones are met; expect 15–25% upside on positive early data/integration, downside of ~20% if programs stall. Use milestone-based tranche buys to limit exposure.
• Long NVO (6–12 months): buy shares or buy 6–12 month calls to play price-led share gains in obesity therapeutics. R/R ~ +12–18% if volume uptake outpaces ASP pressure, downside ~10% if payers push back; size modestly given policy risk.
• Long GOOGL (6–18 months) in preference to uncaptured cloud peers: buy GOOGL or buy 9–12 month call spread. Thesis: owning both software stack and preferential access to custom silicon widens margin optionality; expect 10–20% upside if cloud AI wins accelerate, downside ~15% on slowed adoption or regulatory setbacks.